C4 Therapeutics, Inc.
CCCC
$4.26
-$0.14-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.51% | 0.31% | -12.88% | -3.44% | 18.08% |
| Total Depreciation and Amortization | 4.44% | 7.76% | 13.74% | 12.41% | 2.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.23% | 9.55% | 30.83% | 4.21% | 3.59% |
| Change in Net Operating Assets | -149.14% | -482.87% | -518.36% | -838.71% | -461.01% |
| Cash from Operations | -18.71% | -51.47% | -32.63% | -12.34% | 12.53% |
| Capital Expenditure | -272.78% | -237.22% | -73.61% | 82.39% | 83.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -166.50% | 84.35% | 364.57% | 221.47% | -40.18% |
| Cash from Investing | -169.03% | 83.22% | 360.05% | 233.27% | -39.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,104.21% | 179.79% | -92.46% | -88.74% | -88.58% |
| Repurchase of Common Stock | 0.83% | 0.52% | 7.73% | -92.00% | -92.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -45.70% | -28.27% | -27.89% | 17.63% | 16.95% |
| Cash from Financing | 1,085.27% | 178.80% | -92.38% | -87.05% | -86.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.02% | 126.87% | 36.98% | -82.24% | -195.09% |